Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram

BMC Psychiatry

Volumn 4, Issue , 2004, Pages

  Carey, Paul D ^a   Warwick, James ^a   Niehaus, Dana J H ^a   van der Linden, Geoffrey ^a   van Heerden, Barend B ^a   Harvey, Brian H ^b   Seedat, Soraya ^a   Stein, Dan J ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; SEROTONIN UPTAKE INHIBITOR; DIAGNOSTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BRAIN PERFUSION; BRAIN SCINTISCANNING; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; LIMBIC SYSTEM; MALE; NEUROANATOMY; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PSYCHOPHARMACOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA; THALAMUS; BLOOD FLOW; BRAIN; COMPARATIVE STUDY; DRUG EFFECT; SCINTISCANNING; SEASONAL AFFECTIVE DISORDER; STATISTICS; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; ANXIETY DISORDERS; BRAIN; CITALOPRAM; FEMALE; HUMANS; LIMBIC SYSTEM; MALE; OBSESSIVE-COMPULSIVE DISORDER; PREFRONTAL CORTEX; REGIONAL BLOOD FLOW; SEASONAL AFFECTIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 12944314769     PISSN: 1471244X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-224X-4-30     Document Type: Article

References (38)

1. Lucey JV, Costa DC, Busatto G, Pilowsky LS, Marks IM, EII PJ, Kerwin RW: Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography. Psychiatry Res 1997, 74:25-33.
2. Rauch SL, Savage CR, Alpert NM, Fischman AJ, Jenike MA: The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. Biol Psychiatry 1997, 42:446-452.
3. Kaplan A, Hollander E: A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003, 54:1111-1118.
4. Stein DJ, Seedat S, van der Linden GJ, Zungu-Dirwayi N: Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000, 15 Suppl 2:S31-S39.
5. van der Linden GJ, Stein DJ, van Balkom AJ: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000, 15 Suppl 2:S15-S23.
6. Hendler T, Goshen E, Tzila Zwas S., Sasson Y, Gal G, Zohar J: Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Res 2003, 124: 7-103.
7. Molina V, Montz R, Martin-Loeches M, Jimenez-Vicioso A, Carreras JL, Rubia FJ: Drug therapy and cerebral perfusion in obsessive-compulsive disorder. J Nucl Med 1995, 36: 234-2238.
8. Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter L.R.,Jr.: Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999, 21:683-693.
9. Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter L.R.,Jr.: FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 1998, 84:1-6.
10. Baxter L.R.,Jr., Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, .: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49: 81-689.
11. Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM: Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry 1990, 47:840-848.
12. Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA: Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 2002, 27:782-791.
13. Hoehn-Saric R, Schlaepfer TE, Greenberg BD, McLeod DR, Pearlson GD, Wong SH: Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and nonresponders. Psychiatry Res 2001, 108:89-100.
14. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL: Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry 1989, 46:518-523.
15. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter L.R.,Jr.: Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003, 160:522-532.
16. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter L.R.,Jr.: Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 2002, 59: 50-261.
17. Van der Linden G., van Heerden B, Warwick J, Wessels C, van Kradenburg J, Zungu-Dirwayi N, Stein DJ: Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:419-438.
18. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M: Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002, 59: 25-433.
19. Seedat S, Warwick J, van Heerden B, Hugo C, Zungu-Dirwayi N, van Kradenburg J, Stein DJ: Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 2004, 80:45-53.
20. MB First, RL Spitzer, M Gibbon, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders - Clinician Edition Biometrics Research Department, New York State Research Institute, NY; 1998.
21. Guy W: ECDU Assessment Manual for Psychopharmacology National Institute of Mental Health, Research Branch; 1976:313-331.
22. Liebowitz MR: Social Phobia. Mod Probl Pharmacopsychiatry 1987, 22:141-173.
23. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
24. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995, 8:75-90.
25. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134: 82-389.
26. Friston KJ, Frith CD, Liddle PF, Frackowiak RS: Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991, 11:690-699.
27. Devinsky O, Morrell MJ, Vogt BA: Contributions of anterior cingulate cortex to behaviour. Brain 1995, 118 (Pt 1): 79-306.
28. McDonald AW, Cohen JD, Stenger VA: Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000, 288:1835-1838.
29. Bechara A, Tranel D, Damasio H: Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. Science 1995, 269:1115-1118.
30. Le Doux J: Fear and the brain: Where have we been, and where are we going? Biol Psychiatry 1998, 44:1229-1238.
31. Rauch SL, Baxter LR: Neuroimaging in obsessive-compulsive disorder and related disorders. In Obsessive-compulsive Disorders: Practical Management 3rd edition. Edited by: JenikeMA, BaerL and MinichielloWE. St Louis, MI, Mosby; 1998.
32. Hamner MB, Lorberbaum JP, George MS: Potential role of the anterior cingulate cortex in PTSD: Review and hypothesis. Depress Anxiety 1999, 9:1-14.
33. Rauch SL, Whalen PJ, Shin LM, McInerney SC, Macklin ML, Lasko NB, Orr SP, Pitman RK: Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biol Psychiatry 2000, 47:769-776.
34. Bremner JD: Does stress damage the brain? Biol Psychiatry 1999, 45:797-805.
35. Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS: Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 1999, 156:1787-1795.
36. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC, Schaefer SM, Koger JV, Benca RM, Davidson RJ: Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 2001, 158:405-415.
37. Carey PD, Warwick J, Harvey BH, Stein DJ, Seedat S: Single photon emission computed tomography (SPECT) in obsessvie-compulsive disorder before andafter treatment with inositol. Metabolic Brain Disease 2004, 19:135-144.
38. Saxena S, Brody AL, Schwartz JM, Baxter LR: Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998:26-37.